Sign In
Buy TEVA
$32.83
-0.250 (-0.756%)
At Close: Jun 03, 2026
Teva Pharmaceutical Industries Ltd. (TEVA) is a Top-Ranked Momentum Stock: Should You Buy?
10:51am, Thursday, 15'th Jan 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Commonwealth Equity Services LLC Acquires 122,701 Shares of Teva Pharmaceutical Industries Ltd. $TEVA
03:58am, Thursday, 15'th Jan 2026
Commonwealth Equity Services LLC raised its holdings in Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) by 75.3% during the third quarter, according to its most recent filing with the Securities and
PARSIPPANY, N.J. and TEL AVIV, Israel, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the N
Teva Is No Longer A Turnaround Story, It's A Growth One
08:01am, Wednesday, 14'th Jan 2026
Teva Pharmaceutical (TEVA) remains a Buy, with specialty drugs, margin expansion, and the Royalty Pharma partnership driving further upside despite a 112% rally. TEVA's specialty pipeline—AUSTEDO, U
Teva Pharmaceutical Industries Limited (TEVA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:46pm, Tuesday, 13'th Jan 2026
Teva Pharmaceutical Industries Limited (TEVA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug
12:26pm, Monday, 12'th Jan 2026
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Royalty Pharma plc (NASDAQ: RPRX) announced on Sunday a funding agreement of up to $500 million to accelerate the clinical development of Teva's an
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug
11:10am, Monday, 12'th Jan 2026
Teva strikes a $500M funding deal with Royalty Pharma for the speedy development of its vitiligo candidate, TEV-'408, while keeping global commercial control.
Why Investors Are So Optimistic on Teva
10:46am, Monday, 12'th Jan 2026
Teva Pharmaceuticals stock jumped Monday after the drugmaker issued upbeat guidance and targets for the years ahead.
Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term
10:40am, Monday, 12'th Jan 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time) Richard
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
05:00pm, Sunday, 11'th Jan 2026
PARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Royalty Pharma plc (Nasdaq: R
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference
04:30pm, Monday, 05'th Jan 2026
TEL AVIV, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 44th A
Why a $34 Million Teva Stock Position Signals Confidence in a Long Repair Story
02:03pm, Saturday, 27'th Dec 2025
Prague-based Pale Fire Capital SE added 639,162 shares of Teva in the third quarter. The overall position value increased by $16.53 million from the previous period.
TEL AVIV, Israel, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that S&P Global Ratings ("S&P") has upgraded Teva's long-term issuer credi
Billionaire Stanley Druckenmiller Sold Nvidia and Palantir and Piled Into One of Wall Street's Hottest Drug Stocks Ahead of 2026
03:51am, Wednesday, 24'th Dec 2025
Quarterly-filed Form 13Fs allow investors to track which stocks Wall Street's savviest money managers are buying and selling. Billionaire Stanley Druckenmiller dumped his fund's stakes in AI darlings
